Vertex Pharma's most recent trend suggests a bullish bias. One trading opportunity on Vertex Pharma is a Bull Put Spread using a strike $210.00 short put and a strike $195.00 long put offers a potential 14.5% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $210.00 by expiration. The full premium credit of $1.90 would be kept by the premium seller. The risk of $13.10 would be incurred if the stock dropped below the $195.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.
The RSI indicator is at 64.44 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Vertex Pharma
2 Top Pharma Stocks to Watch in November
Sun, 15 Nov 2020 12:04:00 +0000
With a dedication to research and development, strong profit margins, and solid balance sheets, blue-chip pharma stocks are among the best investment choices during a volatile year. Biogen (NASDAQ: BIIB) encountered an enormous setback recently when a team of panelists from the U.S. Food and Drug Administration (FDA) voted overwhelmingly that the company's aducanumab, which targets Alzheimer's disease, did not demonstrate efficacy in a pivotal phase 3 study. While the FDA will make a final decision of whether or not to approve aducanumab by March 7, the odds are not looking good for Biogen.
Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation
Fri, 13 Nov 2020 21:01:00 +0000
Vertex today has been notified of an unsolicited “mini-tender” offer made by TRC Capital Investment Corporation.
Got $250? 3 High-Growth Stocks on Sale to Buy Now
Fri, 13 Nov 2020 10:51:00 +0000
With its shares down close to 50% in a matter of one month, edge cloud-computing services provider Fastly (NYSE: FSLY) is the perfect example of a high-growth stock that's walked back into the buy range for opportunistic long-term investors. This also coincides with the Trump administration's attacks on TikTok and threats to ban the app stateside. The end result was that Fastly reduced the midpoint of its Q3 sales guidance by $4 million below its previous projection.
Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19
Thu, 12 Nov 2020 21:01:00 +0000
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual London Health Care Conference on Thursday, November 19, 2020 at 9:05 a.m. ET (2:05 p.m. GMT).
5 Top Healthcare Stocks to Buy in November
Thu, 12 Nov 2020 11:53:00 +0000
Compared to other sectors of the market, stocks in the healthcare industry have performed remarkably well this year. Many healthcare stocks have mirrored or surpassed the gains of the S&P 500 amid the market's recovery following the March crash. Given the vital products and services that companies in the healthcare industry provide, from life-saving medications and medical devices to insurance and potential vaccines, it's not surprising that a number of stocks in this sector have remained recession and volatility-proof.
Also on Market Tamer…
Follow Us on Facebook